Provided by Tiger Fintech (Singapore) Pte. Ltd.

enVVeno Medical Corp.

3.31
+0.310010.33%
Post-market: 3.310.00000.00%16:05 EDT
Volume:108.73K
Turnover:352.41K
Market Cap:58.04M
PE:-2.60
High:3.37
Open:3.04
Low:3.02
Close:3.00
Loading ...

Company Profile

Company Name:
enVVeno Medical Corp.
Exchange:
NASDAQ
Establishment Date:
1999
Employees:
37
Office Location:
70 Doppler,Irvine,California,United States
Zip Code:
92618
Fax:
- -
Introduction:
enVVeno Medical Corporation, a clinical-stage medical device company, focuses on the development of various bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous diseases. The company's lead product is the VenoValve, a surgical implant being developed for the treatment of venous Chronic Venous Insufficiency. Its VenoValve is implanted in the femoral vein and acts as a one-way valve to help restore proper blood flow in the leg; and enVVe, a non-surgical, transcatheter based replacement venous valve for the treatment of CVI. The company was formerly known as Hancock Jaffe Laboratories, Inc. and changed its name to enVVeno Medical Corporation in October 2021. enVVeno Medical Corporation was incorporated in 1999 and is based in Irvine, California.

Directors

Name
Position
Robert A. Berman
Director, Chief Executive Officer
Francis Duhay
Director
Matthew M. Jenusaitis
Director
Robert C. Gray
Director
Sanjay Shrivastava
Director

Shareholders

Name
Position
Robert A. Berman
Director, Chief Executive Officer
Craig Glynn
Chief Financial Officer and Treasurer
Hamed Alavi
Senior Vice President and Chief Technology Officer
Marc H. Glickman
Senior Vice President and Chief Medical Officer